傲農生物(603363.SH):擬以9600萬元收購湖北鑫成生物飼料60%股權
格隆匯 9 月 14日丨傲農生物(603363.SH)公佈,公司擬以人民幣9600萬元收購湖北鑫成生物飼料有限公司60%股權。
湖北鑫成主營業務為雞飼料和豬飼料的生產與銷售,進行禽類飼料生產與銷售已有十年,擁有標準工廠化生產工藝流程。主要採用原材料集中採購決策、集中生產佈局、銷售產品和技術服務緊密結合的經營模式。鑫成公司生產的飼料的客户主要為浠水縣域範圍及周邊禽類養殖公司及養殖户。
通過此次交易,有利於公司進一步開拓湖北地區的飼料業務市場,促進公司飼料板塊業務做大做強,符合公司的產業發展戰略和經營規劃。此次股權收購完成後,雙方將在市場、管理、技術、人才等方面整合優勢資源,促進雙方合作共贏,提升公司盈利能力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.